The influence of psychosocial characteristics and race/ethnicity on the use, duration, and success of antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 47, Issue 2, 2008, Pages 194-201

  Pence, Brian Wells ^a   Ostermann, Jan ^a,b   Kumar, Virender ^c   Whetten, Kathryn ^a,b   Thielman, Nathan ^a,b   Mugavero, Michael J ^d  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WESTAT   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

Alcohol use; Antiretroviral therapy; Disparities; HIV; Mental health

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; DISEASE DURATION; ETHNIC DIFFERENCE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; PRIORITY JOURNAL; PSYCHOSOCIAL DEVELOPMENT; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SOCIAL PSYCHOLOGY; SOCIAL STATUS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CONTINENTAL POPULATION GROUPS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PSYCHOLOGY; SOUTHEASTERN UNITED STATES; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 38649138004     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31815ace7e     Document Type: Article

References (44)

1. Palacio H, Kahn JG, Richards TA, et al. Effect of race and/or ethnicity in use of antiretrovirals and prophylaxis for opportunistic infection: a review of the literature. Public Health Rep. 2002;117:233-251 [discussion 231-232].
2. Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA. 1999;281:2305-2315.
3. Gebo KA, Fleishman JA, Conviser R, et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr. 2005;38:96-103.
4. Mocroft A, Madge S, Johnson AM, et al. A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr. 1999;22:369-378.
5. Fairfield KM, Libman H, Davis RB, et al. Delays in protease inhibitor use in clinical practice. J Gen Intern Med. 1999;14:395-401.
6. Turner BJ, Fleishman JA, Wenger N, et al. Effects of drug abuse and mental disorders on use and type of antiretroviral therapy in HIV-infected persons. J Gen Intern Med. 2001;16:625-633.
7. Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17:377-381.
8. Sternhell PS, Corr MJ. Psychiatric morbidity and adherence to antiretroviral medication in patients with HIV/AIDS. Aust N Z J Psychiatry. 2002;36:528-533.
9. Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58:721-728.
10. Li X, Margolick JB, Conover CS, et al. Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr. 2005;38:320-328.
11. Parienti JJ, Massari V, Descamps D, et al. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis. 2004;38:1311-1316.
12. Pence BW, Miller WC, Gaynes BN, et al. Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;44:159-166.
13. Miguez MJ, Shor-Posner G, Morales G, et al. HIV treatment in drug abusers: impact of alcohol use. Addict Biol. 2003;8:33-37.
14. Golub ET, Astemborski JA, Hoover DR, et al. Psychological distress and progression to AIDS in a cohort of injection drug users. J Acquir Immune Defic Syndr. 2003;32:429-434.
15. Ickovics JR, Hamburger ME, Vlahov D, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA. 2001;285:1466-1474.
16. Cohen M, Deamant C, Barkan S, et al. Domestic violence and childhood sexual abuse in HIV-infected women and women at risk for HIV. Am J Public Health. 2000;90:560-565.
17. Whetten K, Leserman J, Lowe K, et al. Prevalence of childhood sexual abuse and physical trauma in an HIV-positive sample from the deep south. Am J Public Health. 2006;96:1028-1030.
18. Mugavero M, Ostermann J, Whetten K, et al. Barriers to antiretroviral adherence: the importance of depression, abuse, and other traumatic events. AIDS Patient Care STDS. 2006;20:418-428.
19. Mugavero MJ, Pence BW, Whetten K, et al. Predictors of AIDS-related morbidity and mortality in a southern US cohort. AIDS Patient Care STDS. 2007;21:681-690.
20. Ickovics JR, Milan S, Boland R, et al. Psychological resources protect health: 5-year survival and immune function among HIV-infected women from four US cities. AIDS. 2006;20:1851-1860.
21. Aral SO, O'Leary A, Baker C. Sexually transmitted infections and HIV in the southern United States: an overview. Sex Transm Dis. 2006;33:S1-S5.
22. Whetten K, Reif S. Overview: HIV/AIDS in the deep south region of the United States. AIDS Care. 2006;18(Suppl 1):S1-S5.
23. Reif S, Geonnotti KL, Whetten K. HIV Infection and AIDS in the Deep South. Am J Public Health. 2006;96:970-973.
24. Centers for Disease Control and Prevention (CDC). HIV/AIDS Surveillance Report, vol. 13 (2001). Atlanta, GA: CDC; 2002.
25. Centers for Disease Control and Prevention (CDC). HIV/AIDS Surveillance Report, vol. 17 (2005). Atlanta, GA: CDC; 2006.
26. Cohen MH, Cook JA, Grey D, et al. Medically eligible women who do not use HAART: the importance of abuse, drug use, and race. Am J Public Health. 2004;94:1147-1151.
27. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, August 13, 2001. Department of Health and Human Services (DHHS); Washington, DC. 2001.
28. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee and Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care. 2000;12:255-266.
29. Leserman J, Whetten K, Lowe K, et al. How trauma, recent stressful events, and PTSD affect functional health status and health utilization in HIV-infected patients in the south. Psychosom Med. 2005;67:500-507.
30. Bernstein D, Fink L. Childhood Trauma Questionnaire Manual. San Antonio, TX: The Psychological Corporation; 1998.
31. Kilpatrick D, Resnick HS. A description of the posttraumatic stress disorder field trial. In: Davidson J, Foa, EB, eds. Posttraumatic Stress Disorder: DSM-IV and Beyond. Washington, DC: American Psychiatric Press; 1993.
32. Felitti VJ, Anda RF, Nordenberg D, et al. Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults. The Adverse Childhood Experiences (ACE) Study. Am J Prev Med. 1998;14:245-258.
33. Derogatis LR, Melisaratos N. The Brief Symptom Inventory: an introductory report. Psychol Med. 1983;13:595-605.
34. Sarason IG, Johnson JH, Siegel JM. Assessing the impact of life changes: development of the Life Experiences Survey. J Consult Clin Psychol. 1978;46:932-946.
35. Leserman J, Petitto JM, Gu H, et al. Progression to AIDS, a clinical AIDS condition and mortality: psychosocial and physiological predictors. Psychol Med. 2002;32:1059-1073.
36. McLellan AT, Kushner H, Metzger D, et al. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat. 1992;9:199-213.
37. Leonhard C, Mulvey K, Gastfriend DR, et al. The Addiction Severity Index: a field study of internal consistency and validity. J Subst Abuse Treat. 2000;18:129-135.
38. Sherbourne CD, Stewart AL. The MOS social support survey. Soc Sci Med. 1991;32:705-714.
39. Pearlin LI, Lieberman MA, Menaghan EG, et al. The stress process. J Health Soc Behav. 1981;22:337-356.
40. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA panel. JAMA. 2000;283:381-390.
41. Finkelhor D. Current information on the scope and nature of child sexual abuse. Future Child. 1994;4:31-53.
42. Himelhoch S, Moore RD, Treisman G, et al. Does the presence of a current psychiatric disorder in AIDS patients affect the initiation of antiretroviral treatment and duration of therapy? J Acquir Immune Defic Syndr. 2004;37:1457-1463.
43. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA. 2006;296:769-781.
44. Whetten K, Zhu CW. Do United States-based Medicaid spend-down programmes make public sense for persons with HIV/AIDS? AIDS Care. 2004;16:781-785.